301
Participants
Start Date
August 31, 2015
Primary Completion Date
November 30, 2016
Study Completion Date
December 31, 2016
CER-001
Engineered pre-beta HDL particle
Placebo
Normal saline
Semmelweiss University, Budapest
Military Hospital, Budapest
Concord Repatriation General Hospital, Concord
Liverpool Hospital, Liverpool
Epworth Research Institute, Richmond
Peninsula Heart Centre, Frankston
University of Debrecen, Debrecen
Royal Adelaide Hospital, Adelaide
Queen Elizabeth Hospital, Woodville South
Flinders Medical Centre, Bedford Park
Pándy Kálmán County Hospital, Gyula
County Hospital of Kecskemet, Kecskemét
Royal Perth Hospital, Perth
University of Szeged, Szeged
Buffalo Heart Group LLP, Buffalo
Veterans Affairs WNY Healthcare System, Buffalo
Novant Health Heart and Vascular Institute, Charlotte
Jacksonville Center for Clinical Research, Jacksonville
Heart Center Research, LLC, Huntsville
Cardiac and Vascular Research Center of Northern Michigan, Petoskey
University of Missouri Health System, Columbia
Cardiovascular Associates Research LLC, Covington
South Oklahoma Heart Research, LLC, Oklahoma City
Dallas VA Medical Center, Dallas
VA Eastern Colorado Health Care System, Denver
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance
VA San Diego Healthcare System, San Diego
Meander Medisch Centrum, Amersfoort
Onze Lieve Vrouwe Gasthuis, Amsterdam
Scheper Ziekenhuis, Emmen
Medisch Centrum Haaglanden, Leidschendam
Canisius-Wilhelmina hospital, Nijmegen
Maasstad Hospital, Rotterdam
Twee Steden hospital (Tilburg), Tilburg
VieCuri Medisch Centrum, Venlo
Lead Sponsor
South Australian Health and Medical Research Institute
OTHER
Cerenis Therapeutics, SA
INDUSTRY